Were Analysts Bearish Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) This Week?

January 16, 2018 - By Vivian Currie

 Were Analysts Bearish Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) This Week?
Investors sentiment increased to 2.16 in Q3 2017. Its up 0.85, from 1.31 in 2017Q2. It improved, as 20 investors sold Portola Pharmaceuticals, Inc. shares while 37 reduced holdings. 38 funds opened positions while 85 raised stakes. 56.33 million shares or 15.80% more from 48.64 million shares in 2017Q2 were reported.
First Advisors L P stated it has 0.01% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Next Gp Incorporated holds 0% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 100 shares. Brown Advisory Inc owns 0% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 8,813 shares. Axa holds 0.01% or 61,000 shares. Principal holds 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) or 62,129 shares. Connecticut-based Sivik Healthcare Limited Com has invested 0.46% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Ameriprise Incorporated has 0% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 31,472 shares. Morgan Stanley holds 0.01% or 333,862 shares in its portfolio. 507 were reported by Pnc Financial Gp Inc. Creative Planning reported 40,426 shares. Manufacturers Life The invested 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Ubs Asset Americas holds 283,129 shares. Evanson Asset Mngmt Lc has 5,000 shares. Laurion Capital Management Ltd Partnership holds 0.11% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 450,118 shares. First Mercantile Trust Communications invested in 7,500 shares or 0.07% of the stock.

Since December 15, 2017, it had 0 insider purchases, and 1 sale for $563,950 activity.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Portola Pharmaceuticals had 32 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer on Wednesday, December 13 with “Buy”. Oppenheimer upgraded the stock to “Outperform” rating in Friday, February 24 report. The stock has “Buy” rating by Oppenheimer on Monday, August 28. The firm earned “Buy” rating on Monday, June 26 by Morgan Stanley. Morgan Stanley maintained the shares of PTLA in report on Friday, October 6 with “Overweight” rating. Credit Suisse maintained it with “Outperform” rating and $29 target in Tuesday, December 27 report. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Buy” rating by Citigroup on Monday, June 26. The company was initiated on Friday, December 18 by Goldman Sachs. On Monday, June 26 the stock rating was maintained by Cowen & Co with “Buy”. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Neutral” rating by Citigroup on Friday, August 19. Below is a list of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) latest ratings and price target changes.

28/12/2017 Broker: Oppenheimer Rating: Buy New Target: $80.0 Maintain
19/12/2017 Broker: Oppenheimer Rating: Buy New Target: $80.0 Maintain
13/12/2017 Broker: Oppenheimer Rating: Buy New Target: $80.0 Maintain
01/12/2017 Broker: Goldman Sachs Rating: Buy New Target: $75.0 Initiate
06/10/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $75 New Target: $81 Maintain
20/09/2017 Broker: Credit Suisse Rating: Buy New Target: $70.0 Maintain
28/08/2017 Broker: Oppenheimer Rating: Buy New Target: $80.0 Maintain
24/08/2017 Broker: Credit Suisse Old Rating: Neutral New Rating: Outperform Upgrade
10/08/2017 Broker: Credit Suisse Rating: Hold New Target: $70.0000 Maintain
10/08/2017 Broker: Oppenheimer Rating: Buy New Target: $80.0000 Maintain

The stock increased 0.55% or $0.29 during the last trading session, reaching $52.62. About 623,664 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since January 16, 2017 and is uptrending. It has outperformed by 34.47% the S&P500.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company has market cap of $3.43 billion. The firm is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It currently has negative earnings. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis.

More notable recent Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news were published by: Globenewswire.com which released: “Portola Pharmaceuticals to Webcast Corporate Update on January 9, 2018” on December 22, 2017, also Seekingalpha.com with their article: “Portola Pharmaceuticals: What The AndexXa Approval Delay Means?” published on December 24, 2017, Prnewswire.com published: “Pre-Market Technical Scan on Biotech Equities — Portola Pharmaceuticals …” on December 19, 2017. More interesting news about Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) were released by: Seekingalpha.com and their article: “Portola Pharmaceuticals: What The Early FDA Approval Of Bevyxxa PAS Entails” published on December 22, 2017 as well as Fool.com‘s news article titled: “Here’s Why Portola Pharmaceuticals Inc. Tanked as Much as 10%” with publication date: December 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: